Australia's Neurizon Therapeutics rise on US patent approval

Neurizon Therapeutics

04/02/2025 23:54

** Shares of Neurizon Therapeutics  NUZ.AX  rise 12% to
A$0.14
    * Stock hit highest level since Jan.20
    ** Biotech firm receives U.S. patent for NUZ-001 for
treatment of neurodegenerative diseases
    ** Adds, patent grant follows FDA's Orphan Drug Designation
for NUZ-001 in May 2024
    ** Stock down 26.5% this year as of last close

 (Reporting by Sherin Sunny in Bengaluru)
 ((Sherin.Sunny@thomsonreuters.com;))